Treating Opportunistic Infections Among HIV
Download
Report
Transcript Treating Opportunistic Infections Among HIV
Guidelines for Prevention and Treatment of
Opportunistic Infections in HIV-Infected Adults
and Adolescents
Syphilis Slide Set
Prepared by the AETC National Resource Center
based on recommendations from the CDC,
National Institutes of Health, and HIV Medicine
Association/Infectious Diseases Society of America
About This Presentation
These slides were developed using recommendations
published in May 2013. The intended audience is
clinicians involved in the care of patients with HIV.
Users are cautioned that, because of the rapidly
changing field of HIV care, this information could
become out of date quickly. Finally, it is intended that
these slides be used as prepared, without changes in
either content or attribution. Users are asked to honor
this intent.
– AETC National Resource Center
http://www.aidsetc.org
2
May 2013
www.aidsetc.org
Syphilis: Epidemiology
Caused by Treponema pallidum
Associated with increased risk of HIV sexual
acquisition and transmission
Increased incidence in men who have sex with
men
HIV infection may somewhat alter diagnosis,
natural history, and management of syphilis, but
principles of management are the same with or
without HIV infection
3
May 2013
www.aidsetc.org
Syphilis: Clinical Manifestations
HIV may make clinical lesions more
apparent and accelerate progression of
syphilis
Primary syphilis
Painless nodule at site of contact, rapidly
ulcerates (chancre)
In HIV-infected patients, may see multiple or
atypical chancres, or no primary lesion
4
May 2013
www.aidsetc.org
Syphilis: Clinical Manifestations (2)
Chancres of primary syphilis
Credit: Centers for Disease Control and Prevention
5
May 2013
www.aidsetc.org
Syphilis: Clinical Manifestations (3)
Secondary syphilis (2-8 weeks after primary
inoculation)
Protean symptoms, may involve almost any organ
system and include:
Rash (macular, maculopapular, papulosquamous, or pustular);
or condyloma lata
Generalized lymphadenopathy
Constitutional symptoms (fever, malaise, anorexia, arthralgias,
headache)
CNS symptoms
Symptoms last days-weeks
In advanced HIV infection, may be more severe or
progress more rapidly
Distinguish from primary HIV infection
6
May 2013
www.aidsetc.org
Syphilis: Clinical Manifestations (4)
Rash of secondary syphilis
Credit: Centers for Disease Control and Prevention
7
May 2013
www.aidsetc.org
Syphilis: Clinical Manifestations (5)
Latent syphilis: no overt signs/symptoms
(but serologic evidence of syphilis), though
relapse of manifestations of secondary
syphilis may occur
Late syphilis: cardiovascular syphilis,
gummatous syphilis; or slowly progressive
disease in any organ system
8
May 2013
www.aidsetc.org
Syphilis: Clinical Manifestations (6)
Neurosyphilis: May occur at any stage of syphilis,
with various symptoms
Cranial nerve dysfunction, stroke, meningitis,
acute or chronic mental status change, loss of
vibration sense, auditory or ophthalmic
abnormalities, similar in HIV-uninfected patients
Concomitant uveitis and meningitis more
common in HIV-positive patients
9
May 2013
www.aidsetc.org
Syphilis: Diagnosis
Direct detection of T pallidum
Darkfield microscopy of mucocutaneous lesion, DFATP, biopsy with silver stain
Presumptive serologic diagnosis tests
Nontreponemal serologic tests (VDRL, RPR)
Treponemal tests (eg, FTA-ABS, TP-PA, EIAs,
chemiluminescence immunoassays)
10
May 2013
www.aidsetc.org
Syphilis: Diagnosis (2)
Testing algorithms:
Traditional: screening for nontreponemal antibodies +
confirmation of reactive tests by treponemal assay
Newer: screening with treponemal test (EIA or CIA),
with reflex nontreponemal test if positive
May identify previously treated syphilis infection more often
than untreated infection
If positive treponemal screening test and negative reflex
nontreponemal test: second treponemal test should be done
(using different antigens) to confirm
If second treponemal test is positive: assess risk factors and
prior syphilis treatment
If suspected primary syphilis: treat empirically, retest with
nontreponemal test in several weeks to confirm diagnosis
If no evidence of primary syphilis: treat for late-latent
syphilis (unless past treatment can be confirmed)
If second treponemal test is negative: no treatment indicated
11
May 2013
www.aidsetc.org
Syphilis: Diagnosis (3)
Early-stage disease:
Nontreponemal serologic tests (VDRL, RPR)
may show atypical responses (higher, lower,
or delayed) in HIV-infected patients
False-negative tests possible (as in HIVuninfected patients); pursue other diagnostic
tests if high suspicion of syphilis (eg, repeat
serology, biopsy, DFA of lesion material;
exclude prozone phenomenon)
12
May 2013
www.aidsetc.org
Syphilis: Diagnosis (4)
Latent syphilis:
Serologic tests positive but no clinical
manifestations
Early latent: evidence of infection <1 year
Late latent: evidence of infection >1 year or
duration is not known
13
May 2013
www.aidsetc.org
Syphilis: Diagnosis (5)
Late-stage disease:
Cardiovascular and gummatous: same
as for HIV-uninfected patients
14
May 2013
www.aidsetc.org
Syphilis: Diagnosis (6)
Neurosyphilis:
All with syphilis (regardless of stage) should be
evaluated for clinical evidence of CNS or ocular
involvement
CSF exam should be done for any patient with:
Neurologic, auditory, or ophthalmic symptoms or signs
Tertiary syphilis
Treatment failure (on basis of serologic tests)
CSF abnormalities (elevated protein, mononuclear
pleocytosis) common in early syphilis and in HIV,
without neurologic symptoms: no evidence that clinical
and prognostic significance is different in HIV-infected
and HIV-uninfected with early syphilis
15
May 2013
www.aidsetc.org
Syphilis: Diagnosis (7)
Neurosyphilis:
No single test used to diagnose; instead, various
combinations of reactive serologic tests, CSF
cell count and protein, and reactive CSF-VDRL
with or without clinical manifestations support
the diagnosis
16
May 2013
www.aidsetc.org
Syphilis: Diagnosis (8)
Neurosyphilis:
CSF examination
Mild mononuclear pleocytosis (6-200 cells/µL),
normal or mildly elevated protein
CSF VDRL
Specific; not sensitive (reactive test establishes
neurosyphilis; nonreactive test does not exclude it)
CSF FTA-ABS
Highly sensitive; less specific (reactive test does not
establish the diagnosis; nonreactive test excludes
neurosyphilis)
PCR-based methods not recommended
17
May 2013
www.aidsetc.org
Syphilis: Diagnosis (9)
Neurosyphilis testing, considerations:
Reactive CSF VDRL plus CSF WBC ≥10 cells/µL
supports diagnosis of neurosyphilis
Mild mononuclear CSF pleocytosis (6-15 cells/µL)
may be associated with HIV infection itself and may
complicate diagnosis of neurosyphilis; using cutoff of
>20 cells/µL may improve specificity of neurosyphilis
diagnosis in HIV-infected patients
Elevated CSF protein concentration should not be
used as sole diagnostic criterion
18
May 2013
www.aidsetc.org
Syphilis: Preventing Exposure
Risk screening should be routine
Client-centered risk-reduction messages; give
specific actions to reduce risk of acquiring STIs
and for transmitting HIV
Routine serologic testing for syphilis at least
annually; Q 3-6 months if multiple partners,
unprotected intercourse, injection drug or
methamphetamine use, or partners with risks
Consider referral for behavioral intervention
Evaluate for other STIs
19
May 2013
www.aidsetc.org
Syphilis: Preventing Disease
For persons exposed sexually to someone with
syphilis: evaluate clinically and serologically and
treat presumptively
Persons exposed within the 90 days preceding
diagnosis of primary, secondary, or early-latent
syphilis in a sex partner may be infected even if tests
are seronegative: treat presumptively
Persons exposed >90 days before diagnosis of
primary, secondary, or early-latent syphilis in a sex
partner: treat presumptively if serologic test results
are not available immediately and follow-up is
uncertain
20
May 2013
www.aidsetc.org
Syphilis: Treatment
Management similar to that for HIV-uninfected
persons, but rates of serologic treatment failure
and neurologic complications may be higher in
HIV infection; closer follow-up is recommended
Penicillin is treatment of choice
Patients with penicillin allergy whose compliance or
follow-up cannot be ensured: desensitize and treat with
penicillin
Use alternatives to penicillin only with close clinical and
serologic monitoring
Azithromycin resistance and treatment failure;
especially in men who have sex with men (MSM)
21
May 2013
www.aidsetc.org
Syphilis: Treatment (2)
Early stage (primary, secondary, early-latent)
Preferred:
Benzathine penicillin G 2.4 million units IM, single dose
Alternative (for penicillin-allergic patients; monitor
closely):
Doxycycline 100 mg PO BID for 14 days
Ceftriaxone 1 g IM or IV QD for 10-14 days
Azithromycin 2 g PO for 1 dose (note: reports of
treatment failure and resistance; should not be used in
MSM or pregnant women)
22
May 2013
www.aidsetc.org
Syphilis: Treatment (3)
Late-latent (no signs of neurosyphilis)
Preferred:
Benzathine penicillin G 2.4 million units IM weekly
for 3 weeks
Alternative (for penicillin-allergic patients):
Doxycycline 100 mg PO BID for 28 days (not
thoroughly evaluated in HIV-infected patients;
monitor closely)
Late-stage (cardiovascular or gummatous)
CSF examination; consult ID specialist
Preferred: Benzathine penicillin G 2.4 million units
IM weekly for 3 weeks
23
May 2013
www.aidsetc.org
Syphilis: Treatment (4)
Neurosyphilis, otic syphilis, ocular syphilis
Preferred:
Aqueous crystalline penicillin G, 18-24 million units
daily, as 3-4 million units IV Q4H or continuous
infusion for 10-14 days
Consider addition of benzathine penicillin 2.4 million units IM weekly
for 3 weeks after completion of IV therapy
Alternative:
Procaine penicillin G 2.4 million units IM QD +
probenecid 500 mg PO QID for 10-14 days
Consider addition of benzathine penicillin 2.4 million units IM weekly
for 3 weeks after completion of above
Patients with sulfa allergy should not receive probenecid, so this
regimen is not recommended for them
Penicillin allergy:
Desensitization to penicillin is preferred; if not feasible,
ceftriaxone 2 g IM or IV QD for 10-14 days
24
May 2013
www.aidsetc.org
Syphilis: Starting ART
No special considerations, no evidence that ART
should be delayed until after treatment for syphilis
IRIS is uncommon
Use of ART associated with:
Decreased risk of serologic failure of syphilis treatment
Lower risk of neurosyphilis
Normalization of CSF parameters after treatment
25
May 2013
www.aidsetc.org
Syphilis: Monitoring and Adverse Events
Monitor clinical and serologic response to treatment;
assure at least 4-fold decline from titer done at time of
treatment:
Early stage: at 3, 6, 9, 12, 24 months
Late-latent: at 6, 12, 18, 24 months
Consider treatment failure: persistence or recurrence in
clinical signs and symptoms or sustained 4-fold increase
in nontreponemal test titer
Neurosyphilis: if CSF pleocytosis present initially, repeat
CSF exam at 6 months; also repeat if symptoms recur or
nontreponemal titer increases by 4-fold
Consider retreatment if no decrease in CSF WBC by 6 months
or if WBC not normal by 2 years
26
May 2013
www.aidsetc.org
Syphilis: Monitoring and Adverse Events (2)
After successful treatment, nontreponemal tests
may remain “serofast,” ie, reactive at stable titer,
usually low (≤1:8)
Sustained ≥4-fold increase in titer indicates
reinfection
27
May 2013
www.aidsetc.org
Syphilis: Monitoring and Adverse Events (3)
Jarisch-Herxheimer reaction may occur in the first
24 hours after start of syphilis treatment
Fever, headache, myalgia
Manage symptoms with antipyretics
Most frequent in those with early syphilis, high
nontreponemal titers, and prior penicillin treatment
28
May 2013
www.aidsetc.org
Syphilis: Treatment Failure
Early stage
Consider CSF evaluation and retreatment if:
≤4-fold decrease in serum nontreponemal test titer 6-12
months after therapy, or
Sustained 4-fold increase in titer after initial 4-fold
reduction after treatment, or
Persistent or recurring signs or symptoms of syphilis
Reinfection is difficult to document and treatment
failure is difficult to rule out
If no appropriate titer response after CSF evaluation
and retreatment, management is unclear
>15% of early syphilis patients (HIV infected and
uninfected) do not have 4-fold decline in titer after
treatment
29
May 2013
www.aidsetc.org
Syphilis: Treatment Failure (2)
Early stage
Retreatment: benzathine penicillin G, 2.4 million
units weekly for 3 weeks (if neurosyphilis present,
treat for that)
30
May 2013
www.aidsetc.org
Syphilis: Treatment Failure (3)
Late-latent stage
Repeat CSF exam and retreat if:
Clinical signs or symptoms of syphilis, or
Sustained 4-fold increase in titer after initial
reduction after treatment, or
≤4-fold decrease in serum nontreponemal test titer
within 12-24 months after therapy
Treatment: benzathine penicillin G, 2.4 million
units weekly for 3 weeks (if neurosyphilis
present, treat for that)
31
May 2013
www.aidsetc.org
Syphilis: Treatment Failure (4)
Neurosyphilis
Consider retreatment if:
CSF WBC count has not decreased 6 months after
completion of treatment, or
CSF WBC count is not normal 2 years after
treatment
32
May 2013
www.aidsetc.org
Syphilis: Preventing Recurrence
Secondary prevention and
maintenance therapy not indicated
33
May 2013
www.aidsetc.org
Syphilis: Considerations in Pregnancy
Screening:
At 1st prenatal visit in all women; in high-prevalence
areas or high-risk women, repeat early in 3rd trimester
and at delivery
Transmission to the fetus and adverse pregnancy
outcomes highest with early-stage syphilis
Pregnancy does not alter the clinical course or
diagnostic test results of syphilis in adults
Syphilis associated with increased risk of
perinatal HIV transmission to infants
34
May 2013
www.aidsetc.org
Syphilis: Considerations in Pregnancy (2)
Use penicillin, if possible, as in nonpregnant HIV-infected
adults
Penicillin is effective for preventing syphilis transmission
to the fetus and for treatment of fetal infection
Optimal penicillin regimen is not clear
In early syphilis, consider second injection of benzathine
penicillin G 1 week after first dose
No alternatives to penicillin proven effective and safe for
treatment of syphilis during pregnancy or prevention of
fetal infection
Pregnant women with syphilis and history of penicillin
allergy should undergo desensitization and treatment
with penicillin
35
May 2013
www.aidsetc.org
Syphilis: Considerations in Pregnancy (3)
Jarisch-Herxheimer reaction in 2nd half of pregnancy
may precipitate preterm labor or fetal distress
In 2nd half of pregnancy, sonographic evaluation for
fetal or placental syphilis
Consult with OB specialists
After treatment, repeat serologic titers in 3rd
trimester and at delivery
Insufficient data on serologic responses after therapy
Treatment likely inadequate if delivery ≤30 days of
treatment, if woman has sign of infection at delivery, or
if maternal titer is 4-fold higher than pretreatment titer
36
May 2013
www.aidsetc.org
Websites to Access the Guidelines
http://www.aidsetc.org
http://aidsinfo.nih.gov
37
May 2013
www.aidsetc.org
About This Slide Set
This presentation was prepared by Susa Coffey,
MD, for the AETC National Resource Center in
June 2013
See the AETC NRC website for the most current
version of this presentation:
http://www.aidsetc.org
38
May 2013
www.aidsetc.org